Olympus 2007 Annual Report Download - page 17

Download and view the complete annual report

Please find page 17 of the 2007 Olympus annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 62

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62

> The main products of the Life Science Business are bio-
logical microscopes, industrial microscopes and clinical
hemanalysis systems.
Sales in the Life Science Business amounted to ¥123,706
million (US$1,031 million), up 14.6% from the previous
fiscal year, and operating income was ¥8,079 million
(US$67 million), an increase of 6.9%. Sales in Europe
and North America contributed to overall results and the
increase in operating income.
Micro-Imaging
Business
> Sales in the micro-imaging (microscopes) business totaled
¥73,938 million (US$616 million), an increase of 17.9%
compared to the previous fiscal year.
In biological microscopes, Olympus recorded vigorous
sales of FLUOVIEW confocal laser scanning microscopes,
a strategic series of microscopes targeting the research
market, in Europe and the United States. Sales of biologi-
cal microscopes were also boosted by stronger demand in
Asian and Latin American research markets.
In industrial microscopes, expansion of the home appli-
ance market in Japan spurred robust sales of flat panel
display inspection equipment, and sales to manufacturers
of semiconductors and electronic components also rose,
mainly in Asia, which led to a revenue increase.
Diagnostic
Systems
> Sales of diagnostic systems climbed 10.1% year on year
to ¥49,768 million (US$415 million).
Sales in the installed-base business combining installa-
tion of clinical chemistry analyzers with continued provi-
sion of reagents were strong in the United States. Sales of
automated chemistry analyzers rose substantially in Asia,
contributing to an overall stronger performance in the diag-
nostic systems business. Olympus also entered the global
market for immunoassay analyzers with the July 2006
release of the AU3000i Immunoassay System and special-
ized reagents in Europe.
Outlook for
Fiscal 2008
> In fiscal 2008, Olympus expects growth in overseas mar-
kets to generate increases in sales and profits in the Life
Science Business. In biological microscopes, Olympus will
continue to focus on sales of high-value-added products
such as the FLUOVIEW. Olympus will complement its micro-
imaging business centered on microscopes with clinical
analyzers and further growth of the bioscience business in
order to expand the scope of its activities as a total system
supplier. Olympus is forecasting sales of ¥130.0 billion
and operating income of ¥8.5 billion in the Life Science
Business.
Life Science Business
science
science
OLYMPUS 2007 15
01-24.indd 1501-24.indd 15 07.8.3 0:16:36 PM07.8.3 0:16:36 PM